Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7454814 | 0.91 | EGFR (0.56) | DDR2PDGFRBPDGFRAEGFRBRAF | |
| SCHEMBL29317831 | 0.89 | KDR (0.52) | DDR2PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL30050285 | 0.88 | DDR2 (0.54) | DDR2PDGFRAFGFR2BRAF | |
| SCHEMBL22972145 | 0.88 | DDR2 (0.54) | DDR2PDGFRAFGFR2BRAF | |
| SCHEMBL22972009 | 0.87 | DDR2 (0.56) | DDR2PDGFRAHTTBRAF | |
| SCHEMBL30049820 | 0.86 | DDR2 (0.44) | DDR2PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL29317833 | 0.86 | DDR2 (0.44) | DDR2PDGFRBPDGFRAFGFR2EGFR | |
| SCHEMBL29317838 | 0.85 | DDR2 (0.79) | DDR2PDGFRABRAF | |
| SCHEMBL30049303 | 0.85 | DDR2 (0.54) | DDR2PDGFRAHTT | |
| SCHEMBL30049538 | 0.85 | DDR2 (0.79) | DDR2PDGFRABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022228549-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | DDR2 4341/4885PDGFRB 4752/4885PDGFRA 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.